Irish-based Amryt Pharma gets boost for drug in France

21st October, 2018

Irish-based drug company Amryt Pharma has said its flagship treatment will now be reimbursed by health authorities in France.

The approval for reimbursement will mean that the drug, Lojuxta, which treats a rare condition that can lead to heart attacks, is now available in five key European countries including Britain, Italy, Germany and Spain.

Analysts at Stifel, which is broker to Amryt, estimate that about 100 people in France have homozygous familial hypercholesterolaemia with about...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Analysis: Zappone row illuminates uncompetitive nature of diplomatic appointments

Politics Daniel Murray 16 hours ago

Analysis: Draft legislation brings individual accountability for financial sector misconduct a step closer

Analysis: The gap between winners and losers in retail is stark

Retail Eugene Kiernan 2 days ago

Vincent Boland: Tycoon space race is boldly going where many have gone before